ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

ASCO’s Lichter Says. Dingell, Stupak Urge FDA To “Act With Due Haste To Avoid Endangering Patients” Steered To ESAs.

March 7, 2008

A Transcript: what Fisher Knew, When Did He Know

June 24, 1994

House Labor-HHS-Ed/ Committee Concerned About Cut In Prevention, Construction Budget

March 20, 1992

DCCR Advisors Okay New Programs; $300,000 Year Demonstrations In Six Communities Supported

November 17, 1978

St. Martin’s Press Buys Rights To Book By Brawley, Goldberg.

March 12, 2010

Upton Leaning to New Division for Centers, Organ Sites, Education

August 25, 1978